Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
112 participants
INTERVENTIONAL
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that individualized fortification of breast milk improves the nutritional intake of preterm infants, optimizing growth, and thus this will positively impact neurodevelopment and health.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study
NCT01305642
Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT03977259
Individualized Nutrition to Optimize Preterm Infant Growth and Neurodevelopment
NCT06266455
Individualized Fortification of Human Milk for Infants Born ≤ 1250 g (MaxiMoM-InForM)
NCT05308134
Human Milk-derived Fortification in Preterm Infants
NCT05228847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individualized fortification of breast milk
1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.
2. Routine fortifier will be added to breast milk batches.
3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Individualized fortification of breast milk
Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
Routine fortification of breast milk
1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.
2. Routine fortifier will be added to breast milk batches.
Routine fortification of breast milk
Infants will be fed routine fortified breast milk.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Individualized fortification of breast milk
Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
Routine fortification of breast milk
Infants will be fed routine fortified breast milk.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Tolerating an enteral intake of ≥ 100 ml/kg/d for ≥ 24h;
3. Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥ 150 mL/kg/d) has been achieved; and
4. Written informed consent has been obtained from the infant's legal representative.
Exclusion Criteria
2. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities;
3. Babies with enterostoma or short gut syndrome;
4. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3);
5. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen 10 mmol/L79 and creatinine of 130 mmol/L80;
6. Hepatic dysfunction, defined by jaundice (direct bilirubin \>1.0 mg/dl) that is associated with one or more abnormal liver function tests (AST, ALT or GGT);
7. Participation in another clinical trial that may affect outcomes of this study; or
8. Probability of transfer to another NICU or level II nursery outside the McMaster Children's Hospital before the minimum period of three weeks is completed.
1. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk;
2. Fluid restriction \< 140mL/kg/d for ≥ 3 consecutive days;
3. Sepsis - all infants with gram-negative sepsis will be removed from the study.
32 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christoph Fusch
Professor and Division Head
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christph Fusch, MD, PhD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
McMaster Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Health Science, McMaster Children's Hospital
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Fabrizio V, Trzaski JM, Brownell EA, Esposito P, Lainwala S, Lussier MM, Hagadorn JI. Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk. Cochrane Database Syst Rev. 2020 Nov 23;11(11):CD013465. doi: 10.1002/14651858.CD013465.pub2.
Rochow N, Fusch G, Ali A, Bhatia A, So HY, Iskander R, Chessell L, El Helou S, Fusch C. Individualized target fortification of breast milk with protein, carbohydrates, and fat for preterm infants: A double-blind randomized controlled trial. Clin Nutr. 2021 Jan;40(1):54-63. doi: 10.1016/j.clnu.2020.04.031. Epub 2020 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201205IFO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.